摘要
目的探讨对眼底黄斑水肿患者采用康柏西普玻璃体腔注射的临床效果。方法选择该院2020年1—12月收治的眼底黄斑水肿患者80例(104眼),按照随机数表法分为两组,玻璃体腔注射雷珠单抗治疗组设为对照组(n=40,52眼)与玻璃体腔内注射康柏西普治疗组设为研究组(n=40,52眼),两组均治疗6个月后,比较临床疗效,检测两组治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、眼压(IOP)水平,并统计两组治疗期间并发症发生情况。结果研究组治疗总有效率为96.15%,高于对照组的84.62%,差异有统计学意义(P<0.05);研究组不良反应发生率为2.50%,低于对照组的20.00%,差异有统计学意义(χ^(2)=4.507,P<0.05)。治疗后研究组BCVA、CMT、IOP水平分别为(0.72±0.22)、(205.91±83.85)μm、(13.67±1.33)mmHg,对照组BCVA、CMT、IOP水平分别为(0.57±0.17)、(247.50±74.68)μm、(14.50±1.54)mmHg,研究组BCVA大于对照组,CMT、IOP水平小于对照组,差异有统计学意义(t=3.891、2.671、2.941,P<0.05)。结论对眼底黄斑水肿患者采用康柏西普玻璃体腔内注射治疗效果理想,能够有效提高患者视力,可改善黄斑中心凹厚度与眼压,且并发症少,治疗安全性高,值得推广。
Objective To investigate the clinical effect of intravitreal injection of Conbercept in patients with macular edema of the fundus.Methods From January to December 2020,80 patients(104 eyes)with fundus macular edema were selected in the hospital,and they were divided into 2 groups according to the random number table method.The intravitreal injection of ranibizumab treatment group was set as the control group(n=40,52 eyes)and the intravitreal injection of Conbercept treatment group was set as the study group(n=40,52 eyes).Both groups were treated for 6 months.The clinical efficacy was compared,the best corrected visual acuity(BCVA),macular foveal thickness(CMT),intraocular pressure(IOP)levels were detected before and after treatment in the two groups,and the complications of the two groups during the treatment period were counted.Results The total effective rate in the study group was 96.15%,which was higher than that in the control group(84.62%),the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 2.50%,lower than that in the control group(20.00%),and the difference was statistically significant(χ^(2)=4.507,P<0.05).After treatment,BCVA,CMT and IOP levels in the study group were(0.72±0.22),(205.91±83.85)μm,(13.67±1.33)mmHg,respectively.BCVA,CMT and IOP levels in the control group were(0.57±0.17),(247.50±74.68)μm and(14.50±1.54)mmHg,respectively.BCVA in the study group was higher than that in the control group,while CMT and IOP levels were lower than that in the control group,the difference was statistically significant(t=3.891,2.671,2.941,P<0.05).Conclusion The effect of intravitreal injection of Conbercept for patients with macular edema of the fundus is ideal,which can effectively improve the vision of the patients,and can improve the thickness of the fovea and intraocular pressure.In addition,there are few complications and high treatment safety,which is worthy of promotion.
作者
李秀芹
LI Xiuqin(Department of Ophthalmology,People's Hospital of Jinxiang County,Jinxiang,Shandong Province,272200 China)
出处
《系统医学》
2022年第1期56-59,共4页
Systems Medicine
关键词
眼底黄斑水肿
康柏西普
玻璃体腔内注射
黄斑中心凹
眼压
并发症
Fundus macular edema
Conbercept
Intravitreal injection
Macular fovea
Intraocular pressure
Complications
